Search

Your search keyword '"Zukotynski K"' showing total 70 results

Search Constraints

Start Over You searched for: Author "Zukotynski K" Remove constraint Author: "Zukotynski K" Search Limiters Full Text Remove constraint Search Limiters: Full Text
70 results on '"Zukotynski K"'

Search Results

1. Worldwide Disparities in Recovery of Cardiac Testing 1 Year Into COVID-19

2. Impact of COVID-19 on the imaging diagnosis of cardiac disease in Europe

4. Impact of COVID-19 on the imaging diagnosis of cardiac disease in Europe

6. Impact of COVID-19 Pandemic on Cardiovascular Testing in Asia: The IAEA INCAPS-COVID Study

7. Impact of COVID-19 Pandemic on Cardiovascular Testing in Asia

11. The value of SPECT in the detection of stress injury to the pars interarticularis in patients with low back pain

13. Worldwide Disparities in Recovery of Cardiac Testing 1 Year Into COVID-19

14. Impact of COVID-19 Pandemic on Cardiovascular Testing in Asia

15. Patterns of failure with 18 F-DCFPyL PSMA-PET/CT in the post-prostatectomy setting: A regional cohort analysis.

16. Wavelet phase coherence of ictal scalp EEG-extracted muscle activity (SMA) as a biomarker for sudden unexpected death in epilepsy (SUDEP).

17. Interreader and Intrareader Reproducibility of 18 F-Flotufolastat Image Interpretation in Patients with Newly Diagnosed or Recurrent Prostate Cancer: Data from Two Phase 3 Prospective Multicenter Studies.

18. Distinct spatial contributions of amyloid pathology and cerebral small vessel disease to hippocampal morphology.

19. A brief overview of targeted radionuclide therapy trials in 2022.

20. Amyloid-PET of the white matter: Relationship to free water, fiber integrity, and cognition in patients with dementia and small vessel disease.

21. Ictal ECG-based assessment of sudden unexpected death in epilepsy.

22. 18 F-DCFPyL (PSMA) PET as a radiotherapy response assessment tool in metastatic prostate cancer.

23. Effect of 18 F-DCFPyL PET/CT on the Management of Patients with Recurrent Prostate Cancer: Results of a Prospective Multicenter Registry Trial.

24. A Peri-Ictal EEG-Based Biomarker for Sudden Unexpected Death in Epilepsy (SUDEP) Derived From Brain Network Analysis.

25. PSMA PET/CT guided intensification of therapy in patients at risk of advanced prostate cancer (PATRON): a pragmatic phase III randomized controlled trial.

26. Management of Differentiated Thyroid Cancer: The Standard of Care.

27. Defining radio-recurrent intra-prostatic target volumes using PSMA-targeted PET/CT and multi-parametric MRI.

29. Somatostatin Receptor Imaging and Theranostics: Current Practice and Future Prospects.

30. A Radiology-focused Review of Predictive Uncertainty for AI Interpretability in Computer-assisted Segmentation.

31. Overview of the First NRG Oncology-National Cancer Institute Workshop on Dosimetry of Systemic Radiopharmaceutical Therapy.

32. Canadian Urological Association best practice report: Prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA PET/CT) and PET/magnetic resonance (MR) in prostate cancer.

33. CCCDTD5: Clinical role of neuroimaging and liquid biomarkers in patients with cognitive impairment.

34. Mars Shot for Nuclear Medicine, Molecular Imaging, and Molecularly Targeted Radiopharmaceutical Therapy.

35. Machine Learning in Nuclear Medicine: Part 2-Neural Networks and Clinical Aspects.

37. Radiographic and metabolic evolution of prostate cancer lung metastasis detected by prostate-specific membrane antigen and fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography.

38. Utilization of Salvage and Systemic Therapies for Recurrent Prostate Cancer as a Result of 18 F-DCFPyL PET/CT Restaging.

40. Clinical and Technical Considerations for Brain PET Imaging for Dementia.

42. Use of a Qualification Phantom for PET Brain Imaging in a Multicenter Consortium: A Collaboration Between the Pediatric Brain Tumor Consortium and the SNMMI Clinical Trials Network.

43. Machine Learning in Nuclear Medicine: Part 1-Introduction.

44. Harmonization of United States, European Union and Canadian First-in-Human Regulatory Requirements for Radiopharmaceuticals-Is This Possible?

45. Pulmonary nodules as incidental findings.

46. Appropriate Use Criteria for 18 F-FDG PET/CT in Restaging and Treatment Response Assessment of Malignant Disease.

48. Response Assessment Criteria and Their Applications in Lymphoma: Part 2.

49. Response Assessment Criteria and Their Applications in Lymphoma: Part 1.

50. Targeted Radionuclide Therapy: Practical Applications and Future Prospects.

Catalog

Books, media, physical & digital resources